MedPath

To Explore the Effectiveness and Feasibility of HERADERM Hydrogel Wound Dressing on Caesarean Section Surgical Site

Completed
Conditions
Wounds and Injuries
Cesarean Section
Surgical Wound Infection
Surgical Wound
Interventions
Device: HERADERM Hydrogel Wound Dressing (Sterile)
Registration Number
NCT06558240
Lead Sponsor
Taipei Veterans General Hospital, Taiwan
Brief Summary

The wound of cesarean section involves multiple layers of tissue and often cause significant postoperative pain. The epidermal wound typically heals within 1 to 2 weeks after surgery. In current clinical practice, advanced wound dressings are commonly used for postoperative wound care. The theory of moist wound healing was first proposed by Winter in 1962, advocating that maintaining a moist environment around the wound can accelerate the healing process.

HERADERM Hydrogel Wound Dressing (Sterile) was approved by the Taiwan FDA in 1999. Although HERADERM Hydrogel Wound Dressing (Sterile) are frequently used clinically for post-cesarean section wound care, there have been no comprehensive reports evaluating the effectiveness and clinical application of the dressings to date. The purpose of this study is to explore the effectiveness and feasibility of HERADERM Hydrogel Wound Dressing on caesarean section surgical site and to provide user experience and clinical data for reference by patients and clinical personnel.

Detailed Description

In this observational, prospective, single-arm study. We aimed to explore the effectiveness and feasibility of HERADERM Hydrogel Wound Dressing (Sterile) on caesarean section surgical site. Written informed consent are obtained before subjects participate in the study. Eligible subjects will be taken initial wound photos and use experimental dressings for postoperative wound care after closure of caesarean section wound site. To evaluate the clinical applicability of the experimental dressings, wound healing assessments will be conducted by independent study nurse during the postoperative period, hospitalization, and follow-up visits. Information of pain intensity experienced by subjects during dressing removal will be collected. Additionally, satisfaction surveys based on subjects' experiences of wearing and changing the experimental dressings will also be collected during the hospitalization and follow-up visits.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
40
Inclusion Criteria
  1. Age over 18, scheduling for a transverse incision cesarean section, and using HERADERM Hydrogel Wound Dressing (Sterile) for wound care at the end of the surgery.
  2. Gestational age over 37 weeks on the day of the cesarean section.
  3. Body mass index (BMI) less than 35 kg/m² on the day of the cesarean section.
  4. Subjects must be able to comply with follow-up wound care visits and subsequent monitoring.
Exclusion Criteria
  1. Subjects unwilling to sign the consent form or with poor compliance.
  2. Currently suffering from severe immune-related skin diseases, such as severe urticaria, generalized eczema, pemphigus, lupus erythematosus, etc.
  3. Using medications that affect wound healing (e.g., glucocorticoids, anticoagulants and immunosuppressive drugs).
  4. Subjects were deemed unsuitable for participation by investigator, such as uncontrolled infection and conditions that interfere with wound healing.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Experimental: HERADERM Hydrogel Wound Dressing (Sterile)HERADERM Hydrogel Wound Dressing (Sterile)Eligible subjects will use experimental dressings for postoperative wound care after caesarean section. The subjects received dressing change on the second day after surgery and on the day of discharge. After discharge, subjects will take home 2 pieces of experimental dressings and change by themselves. (Timing to change dressing after discharge: the area of exudate exceeds two-thirds of the dressing area)
Primary Outcome Measures
NameTimeMethod
REEDA scaleAssessing on post-operative day 2, 4 & 11

The scale includes five factors that indicate abdominal wound healing: redness, edema, ecchymosis, discharge, and approaching wound edges. Each improvement factor is evaluated by giving 0, 1, 2 and 3 points. The sum of the scores obtained as a result of the evaluation of five categories constitutes the REEDA score. The lowest score on the scale is 0, and the highest score is 15. The highest score on the scale indicates severe perineal trauma.

Percentage of surgical wound infectionAssessing on post-operative day 2, 4 & 11 if there are any surgical site infection

The definition of surgical site infection will be according to CDC definitions of nosocomial surgical site infections: a modification of CDC definitions of surgical wound infection.

Secondary Outcome Measures
NameTimeMethod
Intensity of pain during dressing removalAssessing on post-operative day 2, 4 & 11

Pain intensity is assessed by Numerical Rating Scale (NRS). Numerical Rating Scale was a 11-point scale on which 0 represented "no pain" and 10 represented the" worst pain ever".

Incidence of adverse eventsWithin 11 days after surgery

The incidence of postoperative adverse events related to the experimental dressings will be recorded.

Percentage of allergic reaction to experimental dressingsWithin 11 days after surgery

The incidence of allergic reaction related to the experimental dressings will be recorded. The final wound check will be performed by the surgeon at 11 days postoperatively.

Satisfaction surveyAssessing on post-operative day 2, 4 & 11

Subjects' and caregivers' satisfaction survey regarding user experience quantified with the use of a 5-grade scale with 'highly satisfied', 'satisfied', 'uncertain', 'dissatisfied' or 'very dissatisfied'.

Number of dressing changeWithin 11 days after surgery

Subjects will take home 2 pieces of experimental dressings and change by themselves. Number of dressing change will be recorded at 11 days postoperatively.

Trial Locations

Locations (1)

Taipei Veterans General Hospital

🇨🇳

Taipei City, Taiwan

© Copyright 2025. All Rights Reserved by MedPath